This suite of courses looks at the cardiological, renal and metabolic systems and how they are interrelated in the cardio-renal metabolic syndrome (CRM). In 2021, 4 million people were estimated to have a diagnosis of type 2 diabetes and 3 million people have chronic kidney disease (CKD). Alongside this, cardiovascular disease is a leading cause of death in the UK, with 1 in 8 men and 1 in 13 women dying from coronary heart disease each year.
Primary care delivers the majority of reviews of long-term conditions, such as cardiovascular disease and diabetes, but also has a key role in their diagnosis and optimisation. The CRM hub brings a primary care perspective to the latest guidance, including the key 2019 consensus report of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) and the 2022 NICE guidelines on type 2 diabetes. Both of these promote personalised targets and demonstrate a move from a glucocentric approach to one which looks at the broader picture of cardio-renal risk reduction. A podcast discusses these issues in more detail, and 5-minute screencasts address prescribing in the CRM syndrome, including agents that have shown benefits across the cardiorenal metabolic systems, improving outcomes for cardiovascular and renal disease, and reducing hospital admissions for heart failure.
A 15-minute short course presents scenarios in primary care relevant to CRM prescribing, with a particular focus on GLP-1 receptor agonists (GLP-1 RA) and SGLT2 inhibitors (SGLT2i), and is complemented by a further screencast offering top tips for prescribing in cardiorenal metabolic disease.
Learning resources are also available on CKD and heart failure; of particular interest may be the podcast on heart failure with preserved ejection fraction (HFpEF) – a relatively newly described condition where evidence for best practice is still evolving.
